

Haematologica  
HAEMATOL/2019/243238  
Version 3

Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study

Marie José Kersten, Julia Driessen, Josée M. Zijlstra, Wouter J. Plattel, Franck Morschhauser, Pieternella J. Lugtenburg, Pauline Brice, Martin Hutchings, Thomas Gastinne, Roberto Liu, Coreline N. Burggraaff, Marcel Nijland, Sanne H. Tonino, Anne I. J. Arens, Roelf Valkema, Harm van Tinteren, Marta Lopez-Yurda, Arjan Diepstra, Daphne De Jong, and Anton Hagenbeek

Disclosures: The study drug (BV) was provided for the study and the study was funded by Takeda. Takeda did not have any influence on the analysis of the data or the interpretation of the results. Hagenbeek: Millennium/Takeda: Consultancy, Honoraria, Research Funding. Kersten: Millennium/Takeda: Honoraria, Research Funding; Celgene: Honoraria, Research Funding; Roche: Honoraria, Research Funding; Gilead: Honoraria; Kite Pharma: Honoraria; Novartis: Honoraria. Morschhauser: Janssen: Scientific Lectures; BMS: Membership on an entity's Board of Directors or advisory committees; Epizyme: Consultancy; Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees; Roche: Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees. Lugtenburg: Millennium/Takeda: Consultancy, Research Funding; Servier: Consultancy, Research Funding; Roche: Consultancy; BMS: Consultancy; Sandoz: Consultancy; Genmab: Consultancy. Diepstra: Millennium/Takeda: Consultancy, Honoraria, Research Funding. Brice: Millennium/Takeda: Honoraria, Research Funding, Scientific Advisory Board; Roche: Honoraria; BMS: Honoraria, Scientific Advisory Board; MSD: Honoraria, Scientific Advisory Board; Jansen: Honoraria. Hutchings: Consultant/advisor: Roche, Takeda, Celgene, Genmab; Research support: Roche, Takeda, Celgene, Genmab, Novartis, Janssen, Incyte, Genentech. Gastinne: Millennium/Takeda: Honoraria, Gilead, Roche, MSD. Zijlstra: Consultant/advisor: Gilead, Roche, Takeda; Honoraria: Gilead, Roche, Takeda, Janssen. De Jong: Consultant/advisor: Takeda. All remaining authors have declared no conflicts of interest.

Contributions: MJK and AH designed the study; all authors collected the data; JD, MLY and HvT analyzed the data; JD and MJK wrote the manuscript with contributions from all authors, who also interpreted the data, read, commented on, and approved the final version of the manuscript; DdJ and AD performed the central pathology review; JZ, CB, AA and RV organized and performed the central FDG-PET-CT review; MJK and AH supervised the study.